KennethCarlAndersonMD

PubMed

• Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple m...
  Jooeun Bae, Teru Hideshima, Yu-Tzu Tai, Yan Song, Nikhil C Munshi, Paul Richardson, Noopur Raje, Kenneth C Anderson> ;Leukemia. 2024 Apr 15
• A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
  Arghya Ray, Ting Du, Xueping Wan, Yan Song, Sindhu C Pillai, Md Abu Musa, Teng Fang, Jared Moore, Brian Blank, Xiaohui Du, Xi Chen, Robert Warne, Dena Sutimantanapi, F...> ;Blood Cancer Journal. 2024 Apr 9
• Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
  Xuehan Mao, Wenqiang Yan, David Mery, Jiahui Liu, Huishou Fan, Jingyu Xu, Yan Xu, Weiwei Sui, Shuhui Deng, Dehui Zou, Chenxing Du, Shuhua Yi, Frits van Rhee, Bart Barl...> ;American Journal of Hematology. 2024 Apr 1
• Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
  Annamaria Gulla, Eugenio Morelli, Megan Johnstone, Marcello Turi, Mehmet K Samur, Cirino Botta, Selma Cifric, Pietro Folino, Delaney Vinaixa, Francesca Barello, Cole C...> ;Blood. 2024 Mar 29
• Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
  Ghobrial, I., Gormley, N., Kumar, S., Mateos, M., Bergsagel, P., Chesi, M., Dhodapkar, M., Dispenzieri, A., Fonseca, R., Getz, G., Kastritis, E., Kristinsson, S., Mart...> ;Blood Cancer Discovery. 2024 Mar 4
• DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy.
  Selma Cifric, Marcello Turi, Pietro Folino, Cole Clericuzio, Francesca Barello, Tallya Maciel, Kenneth C Anderson, Annamaria Gulla> ;Antioxidants & Redox Signaling. 2024 Mar 22
• Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
  Jiye Liu, Lijie Xing, Jiang Li, Kenneth Wen, Ning Liu, Yuntong Liu, Gongwei Wu, Su Wang, Daisuke Ogiya, Tian-Yu Song, Keiji Kurata, Johany Penailillo, Eugenio Morelli,...> ;Nature Communications. 2024 Feb 14
• Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
  McMillin, D., Delmore, J., Weisberg, E., Negri, J., Geer, C., Klippel, S., Munshi, N., Mitsiades, C., Mitsiades, N., Schlossman, R., Kung, A., Griffin, J., Richardson,...> ;Nature Medicine. 2024 Feb 14
• Role of minimal residual disease assessment in multiple myeloma.
  Munshi, N., Szalat, R., Anderson, K.> ;Haematologica. 2024 Feb 8
• Isatuximab-pomalidomide-dexamethasonepomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
  Richardson, P., Perrot, A., Miguel, J., Beksac, M., Spicka, I., Leleu, X., Schjesvold, F., Moreau, P., Dimopoulos, M., Huang, S., Minarik, J., Cavo, M., Prince, H., Ma...> ;Haematologica. 2024 Feb 1
• Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
  Zhu, D., Wang, Z., Zhao, J., Calimeri, T., Meng, J., Hideshima, T., Fulciniti, M., Kang, Y., Ficarro, S., Tai, Y., Hunter, Z., McMilin, D., Tong, H., Mitsiades, C., Wu...> ;Nature Medicine. 2024 Jan 25
• Shrinking the divide: improving myeloma CART access.
  Ajay K Nooka, Monique A Hartley-Brown, Kenneth C Anderson, Sagar Lonial> ;Blood Advances. 2024 Jan 9
• 1 citations
  BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
  Dutta, D., Liu, J., Wen, K., Kurata, K., Fulciniti, M., Gulla, A., Hideshima, T., Anderson, K.> ;Blood Cancer Journal. 2023 Dec 11
• Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
  Edri, A., Ben-Haim, N., Hailu, A., Brycman, N., Berhani-Zipori, O., Rifman, J., Cohen, S., Yackoubov, D., Rosenberg, M., Simantov, R., Teru, H., Kurata, K., Hendel, A....> ;International Journal of Molecular Sciences. 2023 Dec 7
• 1 citations
  Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8αβ+ T cells targeting multiple myeloma.
  Jooeun Bae, Shuichi Kitayama, Zach Herbert, Laurence Daheron, Keiji Kurata, Kenneth Livak, Shuqiang Li, Mubin Tarannum, Rizwan Romee, Nikhil C Munshi, Shin Kaneko, Jer...> ;Blood. 2024 Mar 7
• Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
  Wenqiang Yan, Jingyu Xu, Huishou Fan, Lingna Li, Jian Cui, Chenxing Du, Shuhui Deng, Weiwei Sui, Yan Xu, Mu Hao, Kenneth C Anderson, Dehui Zou, Lugui Qiu, Gang An> ;Cancer. 2024 Feb 1
• Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
  Sonja I Berndt, Joseph Vijai, Yolanda Benavente, Nicola J Camp, Alexandra Nieters, Zhaoming Wang, Karin E Smedby, Geffen Kleinstern, Henrik Hjalgrim, Caroline Besson, ...> ;Leukemia. 2023 Oct 1
• Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
  Jiahui Liu, Wenqiang Yan, Huishou Fan, Jingyu Xu, Lingna Li, Chenxing Du, Xuehan Mao, Yuting Yan, Yan Xu, Weiwei Sui, Shuhui Deng, Shuhua Yi, Kenneth C Anderson, Lugui...> ;Cancer Research Communications. 2023 Sep 1
• Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
  Paul G Richardson, Brian G Durie, Laura Rosiñol, Maria-Victoria Mateos, Angela Dispenzieri, Philippe Moreau, Shaji Kumar, Noopur Raje, Nikhil Munshi, Jacob P Laubach, ...> ;Haematologica. 2023 Nov 1
• 1 citations
  Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.
  Mehmet Kemal Samur, Anil Aktas Samur, Jill Corre, Romain Lannes, Parth Shah, Kenneth Anderson, Hervé Avet-Loiseau, Nikhil Munshi> ;Blood Advances. 2023 Nov 14
• 12 citations
  Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
  Noopur Raje, Kenneth Anderson, Hermann Einsele, Yvonne Efebera, Francesca Gay, Sarah P Hammond, Alexander M Lesokhin, Sagar Lonial, Heinz Ludwig, Philippe Moreau, Krin...> ;Blood Cancer Journal. 2023 Aug 1
• Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.
  Ola Rizq, Naoya Mimura, Motohiko Oshima, Shuji Momose, Naoya Takayama, Naoki Itokawa, Shuhei Koide, Asuka Shibamiya, Yurie Miyamoto-Nagai, Mohamed Rizk, Yaeko Nakajima...> ;Leukemia. 2023 Sep 1
• 1 citations
  Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multip...
  David J Chung, Nina Shah, Juan Wu, Brent Logan, Lina Bisharat, Natalie Callander, Giulia Cheloni, Kenneth Anderson, Thinle Chodon, Binod Dhakal, Steve Devine, Poorvi S...> ;Clinical Cancer Research. 2023 Dec 1
• Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs.
  Xili Liu, Maria Moscvin, Seungeun Oh, Tianzeng Chen, Wonshik Choi, Benjamin Evans, Sean M Rowell, Omar Nadeem, Clifton C Mo, Adam S Sperling, Kenneth C Anderson, Zahid...> ;Clinical and Experimental Medicine. 2023 Nov 1
• UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.
  Ola Rizq, Naoya Mimura, Motohiko Oshima, Shuji Momose, Naoya Takayama, Naoki Itokawa, Shuhei Koide, Asuka Shibamiya, Yurie Miyamoto-Nagai, Mohamed Rizk, Yaeko Nakajima...> ;Leukemia. 2023 Sep 1
• Join now to see all

Journal Articles

• APRIL Signaling via TACI Mediates Immunosuppression by T Regulatory Cells in Multiple Myeloma: Therapeutic Implications  
  Kenneth C Anderson, Nikhil Munshi, Paul Richardson, Chirag Acharya, Nature
• Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma  
  Nikhil Munshi, Kenneth C Anderson, A Keith Stewart, Sagar Lonial, Blood

Abstracts/Posters

• Results from Phase 1/2 Trial of Tagraxofusp in Combination with Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Altered Genomic and Epigenetic Profiling of Myeloma Bone Marrow Stromal Cells Identifies Targets for Current and Future Immunotherapeutic Approaches
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Development TACI and Bcma Dual-Antigen Targeted Immunotherapy for Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Lack of Significant Differences in Somatic Alterations between MGUS, SMM and Symptomatic Multiple Myeloma: A Result from Comprehensive Genomic Profiling Study
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Anti-Bcma PBD MEDI2228 Combats Drug Resistance and Synergizes with Bortezomib and Inhibitors to DNA Damage Response in Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Interaction of Plasmacytoid Dendritic Cells and Myeloma Cells Trigger Tumor Promoting Transcriptional Changes in Multiple Myeloma Cells
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• The Landscape of Genome Wide Somatic Alterations Identifies a Good-Risk Group in Newly Diagnosed Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expanded Meta-Analyses Confirms the Association between MRD and Long-Term Survival Outcomes in Multiple Myeloma (MM)
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• The Transmembrane Receptor Roundabout 1 (ROBO1) Is Necessary for Multiple Myeloma Proliferation and Homing to the Bone Marrow Niche
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Timing the Initiation of Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• TNF-_ Confers Resistance of Myeloma Cells to IMiDs through TRAF2 Degradation
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Proteomic Analysis Identifies Mechanism(s) of Overcoming Bortezomib-Resistance Via Targeting Ubiquitin Receptor Rpn13
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Syndecan-1 Is Critical in ARF6-Dependent Macropinocytosis Driven By KRAS Mutation in the Pathophysiology of Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• APOBEC3B Induction Following DNA Damage Response Modulates the Survival and Treatment Response in Human Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• AMG 701 Potently Induces Anti-Multiple Myeloma (MM) Functions of T Cells and IMiDs Further Enhance Its Efficacy to Prevent MM Relapse In Vivo
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Loss-of-Function of Gabarap Impairs Bortezomib-Induced Anti-Tumor Immunity in Multiple Myeloma: Clinical Application
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High-Dimensional Heterogeneity of Waldenstr_m Macroglobulinemia within Its Immune Tumor Microenvironment
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Preclinical Validation of Ubiquitin Receptor PSMD4 As Therapeutic Target in Multiple Myeloma
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III Study
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Blockade of Ubiquitin Receptor Rpn13 in Plasmacytoid Dendritic Cells Enhances Anti-Myeloma Immunity
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for Immunotherapy
  Kenneth C. Anderson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Blood and Beyond: Cancer- what it does to you AND for you 
  60th American Society of Hematology Annual Meeting - 12/2/2018
• Approach to the Treatment of the Older, Unfit Patient With Myeloma: From Diagnosis to Relapse 
  60th American Society of Hematology Annual Meeting - 12/1/2018